Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
EMERYVILLE, Calif., June 14 /PRNewswire-FirstCall/ -- Onyx
Pharmaceuticals, Inc. today announced that it will host a teleconference and webcast on
Monday, June 14, 2010, at 9:00 a.m. Eastern Time (6:00 a.m. Pacific
Time) to provide an update on Nexavar® (sorafenib)
or by dialing 847-619-6547 and using the passcode 27265718. A
replay of the presentation will be available on the Onyx website or
by dialing 630-652-3044 and using the passcode 27265718#
approximately one hour after the teleconference concludes. The
replay will be available through June 28, 2010.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company
committed to improving the lives of people with cancer. The
company, in collaboration with Bayer HealthCare Pharmaceuticals,
Inc., is developing and marketing Nexavar® (sorafenib) tablets,
a small molecule drug that is currently approved for the treatment
of liver cancer and advanced kidney cancer. Additionally, Nexavar
is being investigated in several ongoing trials in a variety of
tumor types. Beyond Nexavar, Onyx has established a development
pipeline of anticancer compounds at various stages of clinical
testing, including carfilzomib, a next-generation proteasome
inhibitor, that is currently being evaluated in multiple clinical
trials for the treatment of patients with relapsed or
relapsed/refractory multiple myeloma and solid tumors. ONX 0801, a
targeted alpha-folate inhibitor, and ONX 0912, an oral proteasome
inhibitor, are currently in Phase 1 testing. For more information
about Onyx, visit the company's website at
Nexavar® (sorafenib) tablets is a registered trademark of
Bayer HealthCare Pharmaceuticals, Inc.
Source: Onyx Pharmaceuticals, Inc.
Posted: June 2010